Healthcare
Medical
Pharmaceutical

Novartis

4,354

$88.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.40 (-0.45%) As of 9:48 AM EDT today
-$0.40 (-0.45%) Today

Why Robinhood?

You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!

About NVS

Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

CEO
Vasant Narasimhan
Employees
103,914
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1996
Market Cap
199.52B
Price-Earnings Ratio
28.46
Dividend Yield
2.29
Average Volume
1.63M
High Today
$88.16
Low Today
$87.86
Open Price
$88.05
Volume
108.69K
52 Week High
$99.84
52 Week Low
$69.18

Collections

Healthcare
Medical
Pharmaceutical
Manufacturing
Health
Technology

NVS News

Reuters8h

BRIEF-Novartis Gets European Commission Approval For Enerzair Breezhaler Asthma Treatment

July 7 (Reuters) - Novartis AG: * NOVARTIS RECEIVES EC APPROVAL FOR ENERZAIR® BREEZHALER®, INCLUDING FIRST DIGITAL COMPANION (SENSOR AND APP) THAT CAN BE PRESC
0
BenzingaJul 2

Novartis Settles $678M Fraud Lawsuit Alleging It Bribed Doctors At Company Speaker Events

Novartis AG (NYSE: NVS) has reached a $678 million settlement in a civil fraud lawsuit that alleged the company bribed doctors at speaker events it organized.
0
ReutersJul 1

Novartis pays $729 million to settle U.S. kickback charges

FILE PHOTO: Logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz By Jonathan Stempel NEW YORK (Reuters) - Novartis AG agreed to pay more than $7
0

NVS Earnings

$0.00
$0.52
$1.04
$1.56
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Available Jul 21, Pre-Market

You May Also Like

SGMA
CVI
IBDN
YINN
COLL
ARKR
COLD
JFU
TECB
PAA

More NVS News

MarketWatchJul 1

Novartis finalizes $678 million settlement

Novartis AG on Wednesday said it completed an agreement with the U.S. Attorney's Office for the Southern District of New York, the New York State Attorney Gener
0
ReutersJul 1

Novartis settles U.S. fraud lawsuit over sham speaker programs

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS
0
ReutersJul 1

Amgen defeats Novartis appeal over arthritis drug Enbrel's patents

(Reuters) - A federal appeals court on Wednesday upheld two patents for Amgen Inc’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG’
0
ReutersJul 1

Amgen patents on top-selling arthritis drug Enbrel upheld, shares rise

By Jonathan Stempel (Reuters) - A U.S. appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel in a
0
BenzingaJun 30

Venture capitalists, Purdue innovations, startups establish winning combination for moving life-changing technologies to public

Purdue University is third in startups and 13th in patents according to reports, and will reach 275 startup creations within the coming fiscal year. Purdue Uni
0
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy NVS

Market Price$88.06
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell Novartis stock and options commission-free.
LearnBlogCareersHelpLog InSign Up